Villar A, Farrus B, Giner P, Sedano E, Serradell J, de Caralt M
Rev Esp Oncol. 1981;28(3):395-412.
37 evaluable patients with relapsed head and neck cancer received as treatment Cisplatin alone (18 patients) or Cisplatin + Adriamycin (19 patients). Both regimens consisted of three-weeks-interval courses. Cisplatin was administered at a dose of 100 mg/m2 as an i.v. infusion with prehydration, posthydration, mannitol and furosemide. Cisplatin + Adriamycin combination was administered at doses of 50 mg/m2 Cisplatin and 50 mg/m2 Adriamycin, both drugs the same day. Clinical toxicity was mild with both regimens. Overall hematologic toxicity was moderate but it was severe with regard to red cells. Some cases of renal toxicity were observed with Cisplatin regimen while no case was noticed with Cisplatin + Adriamycin combination. An overall response rate of 44% (4 CR + 4 PR) was achieved with Cisplatin protocol. The mean duration of response was 5,5 months. An overall response rate of 53% (3 CR + 7 PR) was achieved with Cisplatin + Adriamycin protocol. The mean duration of response was 2,75 months.
37例可评估的复发性头颈癌患者接受了治疗，其中18例患者单独使用顺铂治疗，19例患者使用顺铂+阿霉素治疗。两种治疗方案均为每三周一个疗程。顺铂的给药剂量为100mg/m²，静脉输注，同时进行水化预处理、水化后处理，并使用甘露醇和速尿。顺铂+阿霉素联合用药时，顺铂和阿霉素的剂量均为50mg/m²，两种药物在同一天给药。两种治疗方案的临床毒性均较轻。总体血液学毒性为中度，但红细胞毒性严重。顺铂治疗方案中观察到一些肾毒性病例，而顺铂+阿霉素联合治疗方案中未发现肾毒性病例。顺铂治疗方案的总体缓解率为44%（4例完全缓解+4例部分缓解），平均缓解持续时间为5.5个月。顺铂+阿霉素治疗方案的总体缓解率为53%（3例完全缓解+7例部分缓解），平均缓解持续时间为2.75个月。
